INTEGRA LIFESCIENCES HOLDING
IARTNASDAQTrading Snapshot
- Day Range
- $16.45 โ $16.85
- 52-Week Range
- $8.70 โ $20.49
- Volume
- $2.02B
- Avg Volume
- $2.25B
- Shares Outstanding
- 77.8M
- Next Earnings
- Oct 23, 2026
Fundamentals Snapshot
- Annual Revenue
- $1.64B
- Last Q Revenue
- $419M
- P/E Ratio
- -180.5
- P/S Ratio
- 0.8x
- EPS (TTM)
- $-0.09
- Dividend Yield
- 0.00%
- Dilution (1yr)
- โ0.3%
Why Investors Own IART
- โHigh-growth profile โ revenue up +31.8% YoY with expanding US Equity exposure.
- โHealthy economics โ 79% gross margin and 23% free-cash-flow margin.
- โNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
INTEGRA LIFESCIENCES HOLDING
IARTAbout INTEGRA LIFESCIENCES HOLDING
Integra LifeSciences Holdings Corporation is a medical technology company focused on the creation, production, and global distribution of advanced surgical implants and instruments. These products are utilized across various medical fields, including neurosurgery, limb reconstruction, and general surgical procedures. The company operates through two primary business segments: Codman Specialty Surgical and Tissue Technologies. The Codman Specialty Surgical division offers a comprehensive range of neurosurgical and neuro-critical care products. This includes specialized equipment for tissue ablation, dural repair solutions, cerebral spinal fluid management systems, intracranial monitoring tools, and cranial stabilization devices. Additionally, this segment provides surgical headlamps, various instrumentation, and supports these offerings with asset management software, technical assistance, and after-market services. Integra also supplies an extensive catalog of approximately 40,000 surgical instrument designs, along with a wide selection of surgical and lighting products. Its clientele spans hospitals, surgical centers, and extends to dental, podiatry, and veterinary practices. The Tissue Technologies segment specializes in innovative regenerative technology products for the treatment of both acute and chronic wounds. It further provides surgical tissue repair solutions for a multitude of applications, such as hernia repair, peripheral nerve protection and regeneration, and tendon reconstruction. This encompasses a broad array of offerings for skin and wound repair, plastic and reconstructive surgery products, bone grafting materials, and specialized nerve and tendon repair products. Integra LifeSciences distributes its diverse product portfolio internationally, reaching markets throughout the United States, Europe, Asia Pacific, and other global regions. Distribution is managed directly through its dedicated sales forces and various other channels, serving a wide array of healthcare entities including hospitals, integrated health networks, group purchasing organizations, individual clinicians, surgery centers, and other healthcare providers. Founded in 1989, Integra LifeSciences Holdings Corporation is headquartered in Princeton, New Jersey.
Otter Score Breakdown
How it's scoredFive components, each rated 1โ5โ and equally weighted (20%), averaged to a 0โ100 score:๐ Quality โ gross margin๐ Growth โ revenue YoYโ๏ธ Valuation โ P/S ratioโก Momentum โ 30-day price change๐ง Dilution โ 1-yr share issuance (buybacks score higher)Analyst Price Target
โLatest News & Updates
IART or PEN: Which Is the Better Value Stock Right Now?
Investors interested in stocks from the Medical - Instruments sector have probably already heard of Integra LifeSciences (IART) and Penumbra (PEN). But which of these two companies is the best option for those looking fo

Integra LifeSciences Announces 100th Patient Enrolled in AERAยฎ Pediatric Registry
Prospective, multicenter registry advances toward planned enrollment of 300 pediatric patients Prospective, multicenter registry advances toward planned enrollment of 300 pediatric patients

Integra LifeSciences Marks 20 Years of CUSAยฎ Technology with Liver Surgery Education at ACS Clinical Congress 2026
Company to feature surgeon-led educational programming and technologies supporting liver surgery Company to feature surgeon-led educational programming and technologies supporting liver surgery

Here's Why Integra LifeSciences (IART) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Integra LifeSciences Holdings Corporation (IART) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Integra LifeSciences Holdings Corporation (IART) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Integra LifeSciences to Present at the 2026 Wells Fargo Healthcare Conference and the 2026 Morgan Stanley Healthcare Conference
PRINCETON, N.J., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced that Lea Knight, chief financial officer, and Mic